LYON, France, Aug. 26, 2010 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it will expand into the rapidly growing Chinese healthcare market with its Albatherm HIFU device for the treatment of prostate cancer. Ablatherm HIFU will be distributed throughout China by Shaw Han Biomedical Co. Ltd. This exclusive distribution agreement underscores EDAP's global expansion strategy for HIFU in what is the fastest growing medical device market. With the largest population in the world, China represents a significant market for prostate cancer treatment as cancer detection rates rise, awareness of treatment options increases and the expanding aging population garners greater access to healthcare. It is an opportune time to commence the regulatory and marketing process in China for EDAP's robotized, quality-of-life preserving device.
EDAP Expands Ablatherm-HIFU Into China By Entering Exclusive Distribution Agreement
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.